Australia Expands Access to Affordable Medications for Cystic Fibrosis, Blood Cancer, and Thyroid Patients

Canberra, November 1 (Daily Kiran) : The Australian government has announced an expansion of subsidized medications for patients suffering from cystic fibrosis, blood cancer, thyroid diseases, and eye conditions under its Pharmaceutical Benefits Scheme (PBS). Health Minister Mark Butler revealed the changes, which took effect on November 1.

Children aged 6 to 11 years with cystic fibrosis, who weigh less than 30 kilograms, can now use the granule form of the medication Trikafta. This new formulation targets the underlying cause of the genetic disorder and is specifically designed for children who have difficulty swallowing pills. According to government estimates, around 3,300 Australians will benefit from this expanded access each year.

Without PBS subsidy, the cost of a prescription for this medication could exceed AUD 20,300 (approximately USD 14,200). The government has also included Tepezza in the PBS, which is used to treat active and moderate to severe thyroid eye disease, potentially benefiting around 310 Australian patients annually.

Additionally, access to the drug Adcetris has been broadened, offering a new treatment option for patients with advanced CD30-positive classical Hodgkin lymphoma, a type of blood cancer. It is expected to assist approximately 370 individuals each year.

Changes have also been made regarding Repatha, a medication for high cholesterol. Eligible patients can now receive larger quantities under the government’s 60-day prescription plan.

Patients under the PBS will pay a maximum of AUD 25 for a prescription, while those with concession cards will pay AUD 7.70. Since July 2022, the government has approved additional funding for 511 new and revised medications under the PBS.

In a related development, Australia’s Therapeutic Goods Administration (TGA) announced plans to strengthen sunscreen regulations to enhance consumer trust. Proposed reforms include stricter testing requirements, quality standards for specific ingredients, and limits on SPF claims made by cosmetic sunscreens.

The TGA is also reviewing production guidelines to clarify responsibilities and quality expectations for companies, ensuring that sunscreen products sold in Australia are safe, effective, and of high quality. These proposed changes follow a public consultation process conducted from March to May, which garnered nearly 120 responses from industry stakeholders, health experts, and consumer groups.

Australia is among the countries with the highest rates of skin cancer globally. The TGA emphasized that the main goal of these regulations is to protect individuals from harmful ultraviolet (UV) rays and reduce the incidence and impact of skin cancer.